FDA Brief

Warning letters Drugs

FDA warning letter to

Monkeypox-treatment.com

High riskIssued Jan 30, 2023Posted Jan 31, 2023Center for Drug Evaluation and Research | CDER

FDA warned Monkeypox-treatment.com and Eric Sminia for promoting Amazon-linked products as mpox treatments without FDA approval.

What happened

On October 31, 2022, FDA reviewed www.monkeypox-treatment.com and found that the site participates in Amazon Associates and earns commissions by promoting products with mpox treatment claims. FDA cited homepage and category-page statements such as "MONKEYPOX TREATMENT" and product listings for "MONKEYPOX FEVER REDUCER," "MONKEYPOX MUSCLE ACHES & PAIN RELIEF," "MONKEYPOX RASH CREAM," and "MONKEYPOX FATIGUE SUPPLEMENTS." The letter says these claims make the linked products unapproved new drugs and misbranded drugs.

What FDA found

  1. FDA says the website's mpox claims make the linked products unapproved new drugs because they are not generally recognized as safe and effective for that use.

    FD&C Act section 505(a), 21 U.S.C. 355(a); section 201(p), 21 U.S.C. 321(p)
  2. FDA says the products are misbranded because they fail to bear adequate directions for use for mpox, which is not amenable to self-diagnosis and treatment without a licensed practitioner.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5
  3. FDA says causing the introduction or delivery for introduction of these products into interstate commerce is prohibited.

    FD&C Act sections 301(a) and (d), 21 U.S.C. 331(a) and (d)
  4. FDA says doing any act with respect to a drug held for sale after interstate shipment that results in misbranding is prohibited.

    FD&C Act section 301(k), 21 U.S.C. 331(k)

What FDA wants

FDA asks the company to stop selling any unapproved and unauthorized products for mpox and to notify FDA in writing within fifteen working days of the specific steps taken, including an explanation and supporting documents. If the company believes there is no violation, it should include its reasoning and supporting information; if correction cannot be completed in that time, it should state why and give a completion date.

Who should pay attention

  • OTC drug and supplement brands sold through affiliate links
  • affiliate marketers and product-review websites
  • retail and affiliate programs that host product links

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk